Thomas Jefferson University

Jefferson Digital Commons
Department of Neurosurgery Faculty Papers

Department of Neurosurgery

2-1-2022

Degenerative Cervical Myelopathy: Development and Natural
History [AO Spine RECODE-DCM Research Priority Number 2].
Aria Nouri
Enrico Tessitore
Granit Molliqaj
Torstein Meling
Karl Schaller

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/neurosurgeryfp
Part of the Neurology Commons, and the Surgery Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Aria Nouri, Enrico Tessitore, Granit Molliqaj, Torstein Meling, Karl Schaller, Hiroaki Nakashima, Yasutsugu
Yukawa, Josef Bednarik, Allan R Martin, Peter Vajkoczy, Joseph S Cheng, Brian K Kwon, Shekar N Kurpad,
Michael G Fehlings, James S Harrop, Bizhan Aarabi, Vafa Rahimi-Movaghar, James D Guest, Benjamin M
Davies, Mark R N Kotter, and Jefferson R Wilson

Special Issue Article

Degenerative Cervical Myelopathy:
Development and Natural History [AO Spine
RECODE - DCM Research Priority Number 2]

Global Spine Journal
2022, Vol. 12(1S) 3 9S–54S
ª The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/21925682211036071
journals.sagepub.com/home/gsj

Aria Nouri, MD, MSc1 , Enrico Tessitore, MD1, Granit Molliqaj, MD1,
Torstein Meling, MD, PhD1, Karl Schaller, MD1, Hiroaki Nakashima, MD, PhD2 ,
Yasutsugu Yukawa, MD, PhD3, Josef Bednarik, MD, PhD4, Allan R. Martin, MD, PhD5,
Peter Vajkoczy, MD6, Joseph S. Cheng, MD, MS7, Brian K. Kwon, MD, PhD8,
Shekar N. Kurpad, MD, PhD9, Michael G. Fehlings, MD, PhD10 ,
James S. Harrop, MD, MSHQS11, Bizhan Aarabi, MD12, Vafa Rahimi-Movaghar, MD13,
James D. Guest, MD, PhD14, Benjamin M. Davies, MRCS, BSc, MPhil15,16 ,
Mark R. N. Kotter, MD, MPhil, PhD15,16, and Jefferson R. Wilson, MD, PhD10

Abstract
Study Design: Narrative review.
Objectives: To discuss the current understanding of the natural history of degenerative cervical myelopathy (DCM).
Methods: Literature review summarizing current evidence pertaining to the natural history and risk factors of DCM.
Results: DCM is a common condition in which progressive arthritic disease of the cervical spine leads to spinal cord compression
resulting in a constellation of neurological symptoms, in particular upper extremity dysfunction and gait impairment. Anatomical
factors including cord-canal mismatch, congenitally fused vertebrae and genetic factors may increase individuals’ risk for DCM
development. Non-myelopathic spinal cord compression (NMSCC) is a common phenomenon with a prevalence of 24.2% in the
healthy population, and 35.3% among individuals >60 years of age. Clinical radiculopathy and/or electrophysiological signs of
cervical cord dysfunction appear to be risk factors for myelopathy development. Radiological progression of incidental Ossification of the Posterior Longitudinal Ligament (OPLL) is estimated at 18.3% over 81-months and development of myelopathy
ranges between 0-61.5% (follow-up ranging from 40 to 124 months between studies) among studies. In patients with symptomatic
DCM undergoing non-operative treatment, 20-62% will experience neurological deterioration within 3-6 years.
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Conclusion: Current estimates surrounding the natural history of DCM, particularly those individuals with mild or minimal
impairment, lack precision. Clear predictors of clinical deterioration for those treated with non-operative care are yet to be
identified. Future studies are needed on this topic to help improve treatment counseling and clinical prognostication.
Keywords
cervical spondylotic myelopathy (CSM), cord compression, ossification of the posterior longitudinal ligament (OPLL), progression, risk factors

Introduction
Degenerative Cervical Myelopathy (DCM) occurs when progressive arthritic/spondylotic changes narrow the cervical spinal
canal, leading to spinal cord compression and progressive spinal
cord impairment.1-3 The clinical manifestations of this disease
exist on a spectrum of severity; while severely affected patients
may be unable to walk or use their hands, mildly affected
patients may experience only minor symptoms and have a good
quality of life. Understanding of the rate at which patients move
along this continuum without operative treatment—the so-called
natural history of DCM—remains limited.
Knowledge regarding prognosis for progression is vital in
the context of DCM since the goal of operative intervention is
to arrest symptomatic progression and functional decline. In
evaluating whether to perform surgery on a DCM patient with
relatively mild symptoms, the risks of cervical spine surgery
are justified if that individual is at high-risk for deterioration if
managed non-operatively. Conversely, if the risks of deterioration are low, it makes sense to avoid upfront surgery and
closely follow the patient. Therefore, our knowledge surrounding natural history and prognosis is essential for DCM-related
treatment decision making.
Apart from patients with symptomatic myelopathy, another
critical question relates to the prognosis of individuals with
cervical spinal cord compression but without myelopathy or
with minimal impairment. In such individuals–who are increasingly recognized due to the ubiquity of neuroimaging–it is
important to understand the risk of myelopathy development,
or potentially catastrophic spinal cord injury, for purposes of
patient counseling and treatment planning. The lack of clear
clinical guidance in this regard was highlighted in a series of
systematic review and practice guidelines on DCM published
in 2017.4
Here, we provide an overview of topics pertaining to the
natural history of DCM to inform prognosis and decisionmaking. We have summarized the existing evidence and highlighted key knowledge gaps and important opportunities for
research. Wherever possible, we focus discussions on more
recent and higher quality (prospective) studies. A summary
of key natural history studies is highlighted in Table 1.

Natural History of the Cervical Degenerative Process
As with all osteoarthritic disease, cervical spine related degeneration is principally a function of use-intensity, genetics,

environmental/lifestyle factors and time.1,26 This process
begins at the intervertebral disc (IVD), wherein decreased compliance occurs secondary to a reduction of nucleus pulposus
hydration and fibrous transformation. The early phase of this
transformation, highlighted by intranuclear cleft formation, a
precursor to future more extensive degenerative disease, is seen
frequently in young asymptomatic individuals as early as the
third decade.26-30 In addition to fibrous transformation, the
height of the IVD progressively decreases, often in asymmetric
fashion, leading to an unequal distribution of forces across the
endplates, ultimately resulting in remodeling of the vertebral
bones.31 This remodeling takes the form of increased anteroposterior length and decreased vertebral height, osteophyte/
bone spur formation, and in certain circumstances can lead to
disc herniation into the vertebrae (Schmorl’s node) and adjacent vertebral autofusion.27 These disc related degenerative
changes can have a number of downstream consequences contributing to eventual myelopathy: 1) ligamentous changes
including in-folding of the ligamentum flavum, reactional
hypertrophy, calcification, and ossification of the posterior
longitudinal ligament and ligamentum flavum; 2) cervical
alignment changes, including development of kyphosis, scoliosis, hyperlordosis or listhesis, and; 3) reduction in cervical
canal size, with progressive decrease in the space available for
the spinal cord,27,31,32 Figure 1. In addition, it has also been
recently shown that aberrations in the paraspinal muscle morphology, including fatty infiltration, presents as part of the
degenerative process.33
While most individuals will develop some degree of degenerative change within the cervical spine with increased age,
most experience few symptoms. However, in a limited proportion of the general population, severe forms of the aforementioned changes can result in spinal cord compression and
myelopathy development. Another group may experience significant degenerative changes at a localized level, such as a
single disc, with otherwise global preservation of cervical
anatomy.

Risk Factors for Cervical Spine Degeneration and DCM
Development
Given that the development of degenerative disc disease is an
age-dependent process, the principle risk factor for DCM development is age, with an average age of onset in the largest cohorts
is typically approximating the mid 50 s to 60 s years of age.35-37
In addition, males seem to be relatively overrepresented in many

N ¼ 33
2 yr (NR)
Mean
3 yr (90%)
Age ¼ 54 yr
10 yr (78%)
Male ¼ 74%

Bednarik et al7
Kadanka8-11 RCT

3 yr (NR) 4 yr
N ¼ 52,
(NR)
N ¼ 27
Mean age ¼ 55
yr
Male ¼ 75%

N ¼ 64
6 yr (83%)
Mean age ¼ 52
yr (Range,
32-73)
Male ¼ 72%

Nakamura et al15
Retrospective
cohort

5 yr (100%)

Matsumoto
et al13,14
Retrospective
cohort

Lees and Turner12 N ¼ 44
Prospective
Mean age ¼
cohort
NR
(Range, 21-80
yr)
Male ¼ 68%

N ¼ 76
Mean age ¼
65yr
Male ¼ 71%

Barnes and
Saunders6
Retrospective
cohort

8.2 yr (59%)

Follow-up,
Demographics mean (%)

Authors & study
design
1. Myelopathy with evidence of
corticospinal tract dysfunction in the
legs with or without sensory
involvement or radiculopathy
2. Plain radiological changes of cervical
spondylosis
3. Myelographic evidence of a complete
or partial block to the flow of contrast
medium in the cervical spine
4. No other reasonable diagnosis that
had manifested itself on follow-up
examination
1. Clinical signs and symptoms of cervical
cord
Dysfunction
2. MRI criteria for cervical mono- and
multisegmental cord compression
and/or myelopathy due to spondylosis
(including soft disc herniations) with
or without developmentally narrow
spinal canal
3. Age < 75 yr
4. mJOA score > 12
5. Patient’s consent to surgery
1. Radiological and myelographic
evidence of cervical spondylosis with
signs of cord damage
2. Extensor plantar responses
3. All patients with other neurological
diseases such as disseminated
sclerosis, even if spondylosis was also
present, were excluded
1. Diagnosed to have cervical
compressive myelopathy based on
both neurological examination and
MRI findings showing spinal cord
compression
2. Mild paresis
3. JOA � 10
Motor function disability in the upper or
lower extremity or in both (Based on
the motor function evaluation of the
JOA)

Inclusion criteria

Motor JOA

JOA
MRI factors

No scale used

Change in mJOA
score
Subjective patients
own evaluation
10m walk test
Score of daily
activities
Electrophysiology

Change in Nurick
grade
Better, same or
worse Nurick
grade

Outcome measure

Follow-up at (based on JOA):
3-year 31% deteriorated
4-year 37% deteriorated

14.3% (4/28) with collar treatment
worsened and 3/4 were eventually
operated (conversion to surgery
10.7%)
Of note, 10 deaths during study period
with 2 deaths attributed to CSM.

Follow-up at (based on mJOA):
1-year 15.1% deteriorated
2-year 34.5% deteriorated
3-year 26.7% deteriorated
Subjective deterioration:
10-year: 56% vs 45.5%(surgical)
Of note, 17 deaths at 10-years with no
death attributed to CSM.

At follow-up (n ¼ 45):
�13.3% of patients deteriorated
�66.67% of patients same
�20.0% of patients improved
Of note, 10 deaths at study follow-up
with 1 patient death attributed to
CSM.

Natural history estimate

(continued)

Assessed, but no significant factors Follow-up at 6 years
associated with worsening
�3% Deterioration of Lower limb
motor function

No MRI factors predicted
outcome

Not assessed

Deterioration or non-response to
conservative treatment at
3-years (P < .05):
-Younger age
-Lower Torg-Pavlov ratio
-higher mJOA
-taller height
-longer CMCT (abductor digiti
quinti)

Patients that deteriorated:
- Were more often women
(P ¼ .01)
- Range of neck movement is
greater (P < .05)
- Range of head movement is also
higher (P < .01).
- Had greater range of head and
neck motion (P < .01)

Prognostic factors noted
(Significant factors)

Table 1. Summary Table of Natural History Studies. Adapted and Modified From Karadimas, Erwin 87 and Tetreault, Karadimas.5
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Shimomura et al19
Sumi et al20
Prospective
cohort

Sampath et al18
Prospective
cohort

Roberts17
Retrospective
cohort

Oshima et al
Retrospective
cohort

16

Authors & study
design
Outcome measure

1. Motor function JOA scores of � 3 in Motor JOA
both upper and lower extremities
2. Cervical spinal cord compression with
ISI on T2-weighted MRI

Inclusion criteria
More likely to undergo surgery
- Local Slip OR 4.7 (1.67-13.0)
- Segmental lordotic angle <0�
OR 4.5 (1.59-12.8)

Prognostic factors noted
(Significant factors)

-No patient without improvement
1. Myelography diagnosis
Motor disability:
within 5 months of starting
2. Immobilization of the neck in a plastic
1 ¼ moderate
treatment improved with
or metal frame collar preceded by
inconvenience in
continued collar
2- to 3-wk bed rest in hospital
normal daily
immobilization.
activity
2 ¼ activities
severely limited
but able to get
about alone
3 ¼ inability to get
about without
help
4 ¼ bed- or
chair-bound.
Number of
Not assessed
1 yr (74%)*
1. Consultation sought for treatment,
N ¼ 31*
symptoms
not second opinion
Mean age ¼
Patient satisfaction
2. � 8 weeks of symptoms consistent
48.7 yr
Pain severity
with cervical spondylosis
(Range, 21-75)
3. Radiographical evidence of spondylosis Activities of daily
Male ¼ 48%
living
4. � 1 prior surgical or intradiscal
procedures
5. Able to read English at � 8th grade
level and fluent in spoken English
6. Age > 18 yr
7. Absence of ailment preventing
participation
8. Legal US residence, no incarceration,
signed informed consent
N ¼ 70 yy, N 3 yr (80%) yy Mild CSM (mJOA � 13)
JOA MRI factors
Extent of cord compression
¼ 60 zz
6.5 yr (79%)
predicted worsening OR
Mean age ¼
zz
26.6 (1.7-421.5)
55.1 þ/�
11.8 yr
Male ¼ 70%
N ¼ 69*
2.5 yr (NR)
JOA
Increased duration of symptoms
was related with clinical

N ¼ 45
6.5 yr (82%)
Mean age ¼
59 yr
(Range, 35-76)
Male ¼ 60%
** N ¼ 24
3 yr (86%)
Mean age ¼
54.2 yr
(Range, 41-69)
Male ¼ 75%

Follow-up,
Demographics mean (%)

Table 1. (continued)

(continued)

Follow-up at 2.5-year (JOA): �62%
deterioration

Follow-up at 3-year (JOA): �19.6%
deterioration

Follow up at 1-year:
- Average worsening of activities of
conservatively treated patients
(P < .05)

33% (n ¼ 8) worsened, 37.5%
unchanged, 29.2% (n ¼ 7) improved
based on motor disability grading.

Follow-up at 6.5 years
�40% Deterioration of motor function

Natural history estimate
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Martin et al25
Ambispective
Cohort

Matsunaga et al24
Prospective
cohort

Wu et al23
Retrospective
cohort

Wu et al22
Retrospective
cohort

Yoshimatsu et al
Retrospective
cohort

21

Authors & study
design

N ¼ 36; mean
age ¼ 61.8
years; 59%
male
N ¼ 117;
mean age
54.6 years;
54% male

N ¼ 14 140;
mean age ¼
NR; % male
NR
N ¼ 5604;
mean age ¼
60.35 þ 14
years; 70%
male

Mean age ¼ 67
yr
(Range, 42-87)
Male ¼ 51%

Inclusion criteria

Outcome measure

1. CSM based on clinical signs and the
presence of compression on the spinal
cord by MRI
2. Patients self-selected to be in the
conservative treatment group after
treatment opinions were explained to
them
3. All patients except 2 had an initial JOA
score � 13
>1 year; % NR Subjects hospitalized and discharged with Incidence of Spinal
the diagnostic ICD-9 code for CSM
Cord Injury
(721.1) (National Health Research
Institute of Taiwan)
Incidence of Spinal
>3 years;
Subjects hospitalized within the study
% NR
period with a first-time discharge
Cord Injury
summary containing the diagnostic
ICD-9 code for OPLL (723.7x)
(National Health Research Institute of
Taiwan)
Patients hospitalized for OPLL who have
not received spinal intervention
within the previous 6 months
(National Health Research Institute of
Taiwan)
17.6 years
Patients with DCM from OPLL
JOA Nurick
(Range ¼
10-30
years); % NR
2.6 years
Patients seen in surgical consultation
Surgeon’s
(100%)
with DCM with:
assessment
mJOA
1) newly diagnosed (N ¼ 95) or
2) recurrent myelopathy (N ¼ 22) after QuickDASH
previous surgery
JAMAR grip
GRASSPMyelopathy
Electronic gait
analysis
Berg balance
Anatomical MRI

Follow-up,
Demographics mean (%)

Table 1. (continued)

mJOA severity category

Not assessed

Not assessed

Not assessed

deterioration of symptoms
(P ¼ .001)
Patient who did not follow
rigorous conservative
treatment were more likely to
deteriorate (P < .025)

Prognostic factors noted
(Significant factors)

- Neurological deterioration observed in
57% patients with primary DCM; 73%
with recurrent DCM.

- Increased myelopathy was observed in
64% (23/36) patients

- Incidence Risk for hospitalization for
SCI of 4.8/1000 person-years with
OPLL.
- Rate of hospitalization for SCI in
patients with DCM from OPLL was
higher than the rate observed in a
healthy population (0.18/1000
person-years; hazard ratio ¼ 32.2;
10.4-99.0; P < .001).

- Incidence Risk for hospitalization for
SCI 13.9/1000 person-years
(11.6-16.6) for patients with CSM

Natural history estimate
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Figure 1. Spectrum of changes in DCM represented by T2 anatomical MRIs. A, A single-level disc degeneration resulting in spinal cord
compression (D). Also shown here are hyperintensity changes of the vertebral body endplates consistent with type I or II modic changes (M). B,
A patient with ossification of the posterior longitudinal ligament (OP) and disc degeneration (D). C, A patient with severe multi-level bone and
disc degeneration and kyphotic deformity. D, A patient with congenital fusion between C4-5 (C). In addition, there is a retrolisthesis evident at
the inferior end of the fused vertebrae (S) as well as enlargement of the ligamentum flavum (LF). Taken from Nouri et al.34

of the largest DCM cohorts (representing approximately 2/3rds
of patients in the global AOSpine study of operated DCM
patients),36 suggesting that males may be at an elevated risk for
DCM development. This is supported by a large Taiwanese
study showing that the highest incidence of DCM for both males
and females occurred in their 70 s, but with a significant difference in incidence rates between the genders (28.9 for males vs
15.3 for females per 100 000 person-years).22 Some research has
suggested this may be due to anatomical variations in canal/
vertebral-body ratio, but studies on this subject are sparse.38
Clinical series of surgically treated DCM patients have shown
that males more commonly present with more severe degenerative states, more commonly have multilevel compression, and
T2 hyperintensity changes.34 The nature of this association,
however, is not completely clear and may be explained by multiple factors including exposure to certain work-related or environmental factors in males as compared to females.
Several other risk factors for cervical spine degeneration
and DCM development have been investigated in the literature,
with definitive evidence for causal factors remaining limited.1,39 The most relevant of these factors are discussed in
further detail below.
Anatomical cervical cord-canal mismatch. Intuitively, the congenital presence of a narrow spinal canal, also known as
“congenital stenosis” or “developmental canal stenosis” should
predispose individuals to the development of DCM. However,
evidence supporting a clear association between congenital
stenosis and myelopathy development remains sparse.39 Older
criteria for defining a narrow canal anatomically based on
radiographs and cadaver studies set a sagittal width of <1213mm or a Torg-Pavlov ratio <0.80-0.82 for the diagnosis.40-43

While previous research has focused primarily on canal size,
recent studies have recognized that spinal cord size also varies
and have thus argued that relative size of the canal and cord
should be assessed.44,45 The basis of a cord-canal size mismatch is that both a narrow canal and a large spinal cord can
predispose patients to cervical spinal cord compression and
potential myelopathy development.44,46 This knowledge has
resulted in the development of relative parameters based on
MRI that incorporate the size of the spinal cord, including:
space available for the cord (SAC) and spinal cord occupation
ratio (SCOR), Figure 2. Depending on the technique, a cordcanal mismatch can be defined as a SCOR 70% when measured on the midsagittal plane,47 80% on the axial plane,48 or
<5mm of SAC.49 While it has been shown that both the large
cord and smaller canal are risk factors for DCM, it has likewise
been shown that there is greater anatomical variability in canal
size compared to spinal cord size in the population, indicating
that this will be the more common reason for a cord-canal
mismatch.44
The risk of spinal cord compression in patients with a cordcanal mismatch has been attributed to 1) less space within the
canal, which lowers the amount of degenerative changes or
migration of spine structures into the canal that are necessary
for spinal cord compression to occur, 2) less cerebrospinal fluid
cushion that surrounds the spinal cord, which decreases the
ability of the fluid to absorb kinetic forces directed at the spine
throughout movement of the head and neck.44
In the sub-analysis of the international and multicenter
AOSpine studies on patients with DCM surgically treated, the
prevalence of a cord-canal mismatch using a sagittal SCOR
70% was found to be 8.4%, and patients diagnosed with a
cord-canal mismatch at non-compressed sites were found to be

Nouri et al
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Figure 2. Cord-Canal mismatch measurement in 2 different patients based on sagittal T2 MRI. A, Represents a patient without a cord-canal
mismatch with a SCOR calculated at 52.2% ([6.12 þ 5.79]/[11.3 þ 11.5]) � 100. B, The patient has a cord-canal mismatch as evidenced by an
SCOR of 73.0% ([5.61 þ 5.08]/[7.53 þ 7.12]) � 100. Taken from Nouri et al.44

5.4 years younger and presented reduced baseline neurological
function and quality of life.47
Future research is needed to understand the role of genetic
causes of cord-canal mismatch and to gain increased insight
into how mismatch influences myelopathy development and/or
progression.

congenital fusions, adjacent segment disease was preferentially
present at segments toward the center of the cervical spine;
however, despite the higher prevalence rates among DCM
patients, and considering the limited size of the patient population with congenital fusion, no difference in duration of
symptoms or age was found.53

Congenital cervical fusion (Klippel-Feil syndrome). Congenital
fusion of cervical vertebrae, which can be seen in the context
of Klippel-Feil Syndrome (KFS) Figure 3, has a reported prevalence of between 0.5 and 0.7% based on cadaver and imaging
studies.50,51 Although KFS is classically associated with the
triad of a short neck, lower posterior hairline, and restriction
of neck movement, all three of these features are only present in
a minority of cases.51,52 Most commonly, congenital cervical
fusion is encountered incidentally without any of the other
classical clinical features of KFS.
It has been previously hypothesized that patients with congenital fusions are at an increased risk for myelopathy development at the segments adjacent to fusion53-55 because fusion
may increase the biomechanical stress on the adjacent discs and
accelerate degeneration.56,57 A small study has shown a relatively high prevalence rate of congenital fusions among DCM
patients (2.4%) compared to the general population.53 However, no definitive studies exist to establish a clear link between
congenital cervical fusions and increased predisposition to
DCM. The same study also showed that in patients with

Genetic factors. Alterations in gene structure and expression
are known to contribute to disease. Several studies have
investigated for genetic factors associated with DCM, with
the current evidence supporting a genetic basis for development of this condition. The most convincing study of an
underlying genetic predisposition was undertaken by Patel
et al58 who utilized population-based data and cross referenced a genealogic database of over 2 million Utah residents with 10 years of clinical diagnosis data from a large
tertiary hospital. They showed, using the Genealogical
Index of Familiality, a significant excess relatedness for
disease with the relative risk for DCM among first-degree
relatives to be 5.21. While this study did not identify specific genes of interest, it demonstrated that heritability plays
a role in DCM development.
Systematic reviews on genetic factors have supported the
principle of a genetic predisposition to both DCM development
and clinical severity.59,60 Some genetic polymorphisms have
been linked to disc degeneration and spondylosis, while others
are linked to OPLL development. The most recent systematic
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Figure 3. Klippel-Feil syndrome and degenerative cervical myelopathy. A and D, A single fusion of C4-5 seen on T1 MRI and lateral radiograph
of the same patient. B and E, Two non-contiguous fusions between C2-3 and C6-7 on T2 MRI and lateral radiograph. C and F, Two contiguous
fusions between C4-5 and C5-6 on CT and lateral radiograph. Adapted from Nouri et al.53

review and meta-analysis has identified 28 genes of interest
with regards to DCM, including those affecting collagens,27,30,32 Interlukins,1,37,34 Transforming growth factor, 1,2,3 Vitamin D binding protein, Bone morphogenic
protein,2,4,30 Fibroblast growth factor (1, 2) as well as many
others.60 From these, 22 genes were found to be associated with
radiologically defined spinal pathology, predominantly OPLL,
12 associated with clinical DCM development, 8 were found to
have an effect on the radiological severity, 3 had an effect on
clinical severity, and 6 on the clinical response to surgery in
spinal cord disease.60 However, the specific mechanisms by
which these genetic factors affect the natural history remain
incompletely defined because none of the candidates have been
studied sufficiently to provide a high level of evidence, and

most studies have been conducted in isolated populations
(almost all of the studies have been conducted in China, Japan,
and South Korea).60 While these genetic studies have predominately focuses on polymorphisms of specific genes, recent
research has shown that expression of specific microRNA’s
can be applied clinically as a biomarker in the clinical setting.61
Laliberte et al61 has recently shown that greater mir-21-5p
expression was associated with worse surgical prognosis
based on the mJOA at 1 year follow-up. The authors attribute
this effect of mir-21-5p on its presumed pro-inflammatory
mechanism.
While the genetic basis for certain syndromic conditions associated with structural aberrations of the cervical spine is better
described, understanding surrounding relative susceptibility to

Nouri et al
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Figure 4. Dynamic cervical spinal cord compression on MRI. A neutral (A) and flexion (B) and extension (C) T2 MRI showing the effect of
movement on spinal cord compression. Here flexion of the spine unmasks spinal cord compression not clear in neutral imaging. Taken from—
Lao et al.71

myelopathy development with most of these conditions remains
incomplete. As examples, patients with Klippel-Feil Syndrome,
Down’s Syndrome (atlanto-axial abnormalities),62 Ehlers Danlos
Syndrome (Hypermobility)63,64 and Achondroplasia (congenital
cervical stenosis)65 have an inherited predisposition for cervical
spine anomalies, many of which can lead to cervical canal narrowing. However, the relative risk of symptomatic myelopathy
development among patients with these conditions, as compared
to nonaffected individuals, remains largely unknown.
Given the current evidence, genetic factors likely influence
DCM development, severity, and recovery potential, however,
validation studies with genetically distinct populations will
need to be undertaken before these research findings can be
applied to clinical practice.
Role of minor trauma, cervical instability and motion on the
development of DCM and spinal cord injury. Although clinical
deterioration may occur spontaneously, DCM patients are at
risk of developing acute spinal cord injury (SCI) in case of
physical trauma (i.e. fall or motor vehicle accident). This
increased risk is thought to be secondary to several factors,
including the presence of spasticity and gait unsteadiness that
increase the propensity for falls, and the presence of preexisting canal narrowing and spinal cord compression. A recent
systematic review showed that the incidence of hospitalization
for SCI in Taiwan was 13.9 and 4.8 per 1000 person-years in
patients with DCM and myelopathy secondary to OPLL,
respectively.22,5,23 The rate of hospitalization of SCI in patients
with myelopathy from OPLL was significantly higher than the
rate observed in a healthy population (hazard ratio of 32.2).5
Contrary to these findings, a prospective study by Bednarik,
Sladkova66 did not show a relationship between traumatic

events and myelopathy onset in 199 patients with initial asymptomatic spinal cord compression. During the study, 14 patients
experienced traumatic events at an average of 44-months
follow-up, but none were associated with immediate neurological deterioration.
Aside from more dramatic or catastrophic instances of traumatic SCI, it has been suggested that minor traumatic events,
leading to significant head and neck movements, may cause
episodes of decline or may be the precipitating event causing
neurological deterioration in patients with known DCM.1,66-68
Movement-based spinal cord trauma can be explained by
changes in the cross-sectional diameter of the spinal canal
during flexion and extension,69 Figure 4. In a cohort of patients
with neck pain, with or without neurological symptoms, studied with dynamic MRI, Hayashi, Wang70 reported a high level
of missed stenosis in the neutral position, and that dynamic
stenosis was discovered in 8.3% of vertebral segments only
when in extension, and 1.6% only when in flexion. They noted
that missed stenosis occurred most commonly at the C5-6 segment. Cervical range of motion in those with stenosis has also
been implicated as a factor. Matsunaga, Kukita68 showed that
myelopathy was present in all patients with OPLL with stenosis
<6mm and that no myelopathy was present in those with canal
diameters of  14mm; however, when the canal diameter was
>6mm but <14mm, myelopathy preferentially developed in
those with increased range of cervical motion.
Repetitive spinal cord compression events resulting from
cervical instability in the setting of cervical spondylolisthesis
has also been suggested to be a potential marker of worse
disease severity and as a potential cause of neurological deterioration in DCM patients. This was recently highlighted by a
sub-analysis of the AO Spine International studies on DCM,
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Figure 5. Prevalence of asymptomatic spinal cord compression among different demographic groups. Taken from Smith et al.76

showing that patients with spondylolisthesis present with worse
neurological function at baseline, and when propensity
matched on other key variables, presented with worse neurological outcomes than patients without spondylolisthesis.72 A
recent systematic review on this topic corroborated these
results.73 It is possible that this subset of patients undergoes
an alternative natural disease course highlighted by an accumulation of minor traumatic events; this, however, remains
speculative.

Natural History of Non-Myelopathic Spinal Cord
Compression (NMSCC)
As discussed above, age-related cervical degenerative changes
occur commonly, often leading to some degree of spinal canal
narrowing or spinal cord compression. However, most patients
with spinal canal narrowing or spinal cord compression do not
have clinical signs and symptoms of myelopathy [nonmyelopathy spinal cord compression (NMSCC)].
In a Japanese MRI study of 1,211 asymptomatic volunteers
ranging between the 2nd and 7th decade, NMSCC was
observed in 5.3% of the study participants, with a second Japanese study finding cord compression in 7.6% of 497 asymptomatic persons undergoing MRI.26,45 However, more recent
studies have shown a much higher incidence of asymptomatic
spinal cord compression, particularly in older patients. Kovalova, Kerkovsky74 noted NMSCC in 57.9% of 183 volunteers
older than 40 years undergoing cervical MRI. Similarly, a subanalysis of 40 non-myelopathic control subjects in a prospective DCM imaging study discovered that 20 of these

asymptomatic patients had MRI evidence of spinal cord compression (defined as indentation, flattening, or torsion). 75
Furthermore, the latter study showed that these NMSCC
patients had macrostructural and microstructural changes
(based on advanced imaging techniques) similar to those
observed in symptomatic DCM. The large discrepancy in prevalence rates between these studies is challenging to interpret.
However, it is likely that variations in diagnostic criteria for
NMSCC between studies, as well as differences between the
ethnic populations studied, may explain the heterogeneity. Specific prevalence rates of asymptomatic spinal cord compression
among different study population demographics have recently
been presented in a meta-analysis,76 Figure 5. Based on this
analysis, the prevalence of NMSCC in a healthy population is
24.2%, and 35.3% in individuals >60 years.76
The key question when considering patients with NMSCC
relates to their likelihood of developing myelopathy over time.
Of the 20 NMSCC patients discussed in the imaging study
above, 2 (10%) eventually developed symptoms of myelopathy
at a median follow-up of 21-months. In the largest prospective
study performed to date on this topic, Bednarik et al found that
among 199 patients enrolled with NMSCC, 8% at 1-year
follow-up and 22.6% at a median of 44 months follow-up
(Range 2-12 years) developed symptoms of myelopathy.77 In
this study, factors shown to be predictive of myelopathy development in multivariate survival analysis at 1-year follow-up
included: the presence of clinical cervical radiculopathy, prolonged somatosensory and motor evoked potentials, and the
absence of spinal cord T2 hyperintensity on MRI. Interestingly,
at longer-term follow-up (44-months), the presence of T2
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hyperintensity on MRI portended a higher risk of myelopathy
development. Hence, the importance of T2 signal change in
predicting the risk of clinical progression remains unknown.
In another study by the same group in 2017, wherein 13.4% of
patients (15/112) developed DCM at a median follow-up of 36months, multivariate analysis showed that radiculopathy, axial
cross-sectional area  70.1mm2, and compression ratio (CR,
anteroposterior size/transverse size of the cord on axial imaging)  0.4  0.4 was predictive of DCM development.78 The
difference in the rate of progression and significant predictors
could be influenced by a different recruitment strategy of
NMDCC patients in these studies. The former study included
patients referred to a center for radiculopathy or cervical pain
(i.e. without myelopathic symptoms or signs, but not clearly
asymptomatic) and has more severe radiological compression
in contrast to the latter one recruited randomly as a part of the
epidemiological study. While it is notable that many of the
predictors reported have differed with follow-up time, the presence of radiculopathy has remained a consistent predictor
across studies. In addition to clinical radiculopathy, electrophysiological measures, including prolonged SSEPs and MEPs, are
associated with an increased rate of myelopathy development,
and their presence has been suggested as a potential indication
to consider surgery for patients with NMSCC.79
Further work is needed to understand the prevalence of
NMSCC more precisely, as well as rates of deterioration, and
to identify key biomarkers (i.e., clinical, imaging, genetic, and
electrophysiological factors) that predict clinical course for
purposes of aiding clinical communication, facilitating treatment decisions, and gauging the optimal follow-up interval for
those who are observed over time. Ultimately, this information
would be critical to direct updates to the guidelines on the
management of these patients, which are currently based on
limited evidence.80

Progression of Asymptomatic OPLL and Myelopathy
Development
While the prevalence of OPLL varies significantly depending
on the region of the world and ethnicity considered (approximately 1.3% among Caucasians and 6.3% among Japanese),
clinical experience dictates that only a fraction of patients
with this ligamentous aberration are symptomatic and require
treatment.81 From a radiographic progression perspective, a
recent retrospective cohort study from Japan reported on 109
individuals with incidentally discovered OPLL. At a mean
follow-up of 80.8-months, the incidence of OPLL progression
was 18.3%, defined as an increase of >2mm in the sagittal
thickness and/or the length of the ossification.82 Risk factors
for progression included younger age at diagnosis, higher
serum uric acid levels, OPLL involvement of  3 vertebral
levels, and continuous type of OPLL, whereas progression
was less common in individuals with a segmental type of
OPLL. 82 Another study of conservatively treated OPLL
patients with no or “slight” myelopathy also found that
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younger age was a significant predictor of OPLL progression,
in addition to higher body weight and BMI.83
In another recent study, Park et al84 reported a progression
rate of 26.8% in vertical dimensions and 22.7% in anteroposterior dimensions after a mean follow-up of 39.3 months.
In this study, younger age at diagnosis and presence of OPLL at
C2-3 were found to be among the variables predicting higher
risk of radiographic progression. They also noted that segmental progression of an ossified mass occurred with increased
segmental range of motion (5 ).
Although radiographic progression of OPLL is of importance, the greater clinical concern relates to the risk of myelopathy development among patients with asymptomatic OPLL.
Unfortunately, estimates surrounding this question are
extremely imprecise and based on low-quality evidence. A
previous systematic review79 and recent studies have reported
a large range of myelopathy development, ranging from 0% in
subjects (0/27) followed for a mean of 59 months85 to 61.5%
in subjects (96/156) with a mean 123.6-month follow-up.86 In
addition, the recent study by Park et al84 demonstrated that
9.3% of patients had mild myelopathy at a mean follow-up of
39.3 months and that an additional 2.1% of patients were
operated on myelopathy during the study period. Risk factors
for myelopathy development included canal stenosis of
60%, lateral deviated OPLL, and increased cervical range
of motion.86

Progression of DCM in Non-Operatively Treated Patients
When considering the topic of DCM, perhaps the greatest clinical knowledge gap relates to the management of patients with
mild DCM. Recent guidelines suggest either surgery or clinical
observation to be reasonable initial treatment options.80 The
central question underlying our treatment decision for mild
DCM patients is: what will happen if we do not intervene with
surgical decompression? Apart from mild patients, more
severely affected patients, for a variety of reasons, may also
not undergo surgery; for purposes of quantifying expectations
for the future, attaining a sound understanding of natural history for this group is important.
The sparse and largely low-quality evidence currently available provides imprecise estimates surrounding the expected
clinical course for patients with symptomatic myelopathy
treated non-operatively. Systematic reviews of the literature
have shown that conversion to surgery for non-operatively followed patients ranged between 4% to 40% over 3-7 year
follow-up periods.5 From the perspective of clinical progression, the available literature suggests that 20-62% of DCM
patients treated non-operatively will experience neurological
deterioration as assessed by the mJOA over 3-6 years of follow-up.87 However, most of these studies used JOA or mJOA
to define neurological progression without considering the
minimal detectible difference (MDD), which appears to be
greater than 1 point based on reliability studies.88,89 A recent
study using an array of measures of spinal cord function found
that 57% of DCM patients deteriorate over a mean follow-up of
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2.5 years, with quantitative measurement of hand grip strength,
hand dexterity, electronic gait analysis, and balance showing
the greatest sensitivity to deterioration.25 Factors influencing
the imprecision of current estimates include significant
between study variations in duration and rates of follow-up,
definition of clinical change or deterioration, and the specifics
of cohort composition as it relates to the severity of symptoms
and underlying pathology. The inexact nature of these estimates leaves clinicians in a difficult situation when attempting
to counsel patients about the relative merits of operative vs.
non-operative treatment.
In addition to understanding rates of clinical progression, it
is also important for clinicians to understand predictors of
deterioration with non-operative care so that those at the highest risk may be selectively targeted with early surgery. While
several studies have investigated potential predictors of neurological deterioration, few variables have reliably demonstrated
importance in this regard.16,19,90 Circumferential compression
of the spinal cord has been shown to be predictive of myelopathy progression.90,19 Likewise, an increased range of motion,
which interestingly has also been related with OPLL progression, as previously noted, has also been suggested to predict
neurological decline.16 From an electrophysiological perspective, normal central motor conduction time has been shown to
predict lack of neurological decline in mild myelopathy
patients treated without surgery.90 Other factors, such as age
and the presence of T2 hyperintensity on MRI have not reliably
predicted the clinical course of patients treated nonoperatively.87,90,19
In a recent study, quantitative MRI (qMRI) techniques,
including white to gray matter ratio, fractional anisotropy and
cross-sectional assessment were shown to detect myelopathy
progression (Progression was defined as patients’ subjective
impression, 2-point mJOA decrease, 3 clinical measures worsening 5%, increased compression on MRI, or 1 of 10
qMRI measures or composite score worsening) with a higher
sensitivity than mJOA.91 This study highlighted that while
patients may seem stable neurologically by conventional measures, disease progression not appreciated by less sensitive
clinical measures may be occurring.
Although a significant proportion of patients with DCM
treated non-operatively will deteriorate over time, it is also
clear within the literature that a sizable proportion will remain
stable over time. A new line of evidence is emerging that may
help to explain this clinical stability, showing that “supraspinal” and cortical changes may facilitate adaptation of neurological function.92,93 It has been recently suggested that a
“functional reserve capacity,” which is facilitated by new cortical motor connection in the supplementary motor region, may
provide a compensatory mechanism in patients with spinal cord
compression and may mask spinal cord sufferance.92 While
further work to support these findings is necessary, such a
mechanism may help to explain the clinical stability, or even
occasional clinical improvement, in neurological status seen in
DCM patients, despite ongoing spinal cord compression.
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Conclusion and Future Directions
Degeneration of the cervical spine progressing to spinal cord
compression, and subsequently development of myelopathy,
represents a continuum of disease progression that remains
incompletely understood. Furthermore, despite the ubiquity
of spinal cord compression due to degenerative cervical spine
disease, our understanding surrounding the frequency of clinical deterioration with non-operative care—the natural history
of this condition—remains limited. This knowledge gap hinders clinicians’ ability to adequately counsel patients. A number of ongoing studies are underway to address this knowledge
gap including a Canadian multicenter prospective longitudinal
study that assesses the natural history of patients with mild
myelopathy treated with initial non-operative care (DCM-NH
study). Started in 2019, and now at about 30% of the 220
subject target sample size, this study will follow mild DCM
patients for up to 5 years to understand the true rate of clinical
change for this patient group. This study, in addition to others,
also investigates the utility of microstructural MRI variables, in
addition to blood biomarkers, to predict the clinical trajectory
of DCM patients treated non-operatively. In addition to clinical, imaging and blood biomarker related variables, electrophysiological parameters such as sensory and motor evoked
potentials are becoming increasingly used and reported as a
means to assess spinal cord sufferance and predict clinical
course.2,3 It is anticipated that incorporation of these and other
tools may permit a more individualized estimate for disease
progression facilitating personalized treatment recommendations for DCM patients based on their specific risk for clinical
deterioration.
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